Evidence map›Paper›PMID 32971946›Full record

ArticleCancers2020

Development and Internal Validation of a Multivariable Prediction Model for Adrenocortical-Carcinoma-Specific Mortality.

Madeleine H T Ettaieb, Sander M J van Kuijk, Annelies de Wit-Pastoors, Richard A Feelders, Eleonora P M Corssmit, Elisabeth M W Eekhoff, Paul van der Valk, Henri J L M Timmers, Michiel N Kerstens, Heinz-Josef Klümpen and 3 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Madeleine H T EttaiebDepartment of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.ORCID 0000-0003-2577-4187
Sander M J van KuijkDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, 6229 Maastricht, The Netherlands.
Annelies de Wit-PastoorsDepartment of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.
Richard A FeeldersDepartment of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 Leiden, The Netherlands.
Eleonora P M CorssmitDepartment of Internal Medicine, Division of Endocrinology, VU Medical Center, 1081 Amsterdam, The Netherlands.
Elisabeth M W EekhoffDepartment of Pathology, Location VU Medical Center, Amsterdam University Medical Centers, 1081 Amsterdam, The Netherlands.
Paul van der ValkDepartment of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
Henri J L M TimmersDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands.
Michiel N KerstensDepartment of Medical Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, 1105 Amsterdam, The Netherlands.
Heinz-Josef KlümpenDepartment of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.
van Rachel S LeeuwaardeDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Maastricht University Medical Center, 6229 Maastricht, The Netherlands.
Bas HavekesDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 Rotterdam, The Netherlands.
Harm R HaakDepartment of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.ORCID 0000-0001-7385-9359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) has an incidence of about 1.0 per million per year. In general, survival of patients with ACC is limited. Predicting survival outcome at time of diagnosis is a clinical challenge. The aim of this study was to develop and internally validate a clinical prediction model for ACC-specific mortality. Data for this retrospective cohort study were obtained from the nine centers of the Dutch Adrenal Network (DAN). Patients who presented with ACC between 1 January 2004 and 31 October 2013 were included. We used multivariable Cox proportional hazards regression to compute the coefficients for the prediction model. Backward stepwise elimination was performed to derive a more parsimonious model. The performance of the initial prediction model was quantified by measures of model fit, discriminative ability, and calibration. We undertook an internal validation step to counteract the possible overfitting of our model. A total of 160 patients were included in the cohort. The median survival time was 35 months, and interquartile range (IQR) 50.7 months. The multivariable modeling yielded a prediction model that included age, modified European Network for the Study of Adrenal Tumors (mENSAT) stage, and radical resection. The c-statistic was 0.77 (95% Confidence Interval: 0.72, 0.81), indicating good predictive performance. We developed a clinical prediction model for ACC-specific mortality. ACC mortality can be estimated using a relatively simple clinical prediction model with good discriminative ability and calibration.

Indexed as

adrenocortical carcinomamortalityprediction

Identifiers

PMID32971946
PMCPMC7564668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.